ATNM - Actinium Pharmaceuticals rises 2% after sees 67% ORR in first cohort in Actimab-A/venetoclax combination trial

Actinium Pharmaceuticals ([[ATNM]] +1.2%)  announced its first-in-human data from the first dose cohort of the Phase 1 portion of the Actimab-A + venetoclax combination Phase 1/2 trial for patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML).Data was presented at the 62 American Society of Hematology ((ASH)) annual meeting. The poster presentation highlighted results from the first three patients treated with the initial subtherapeutic dose level of 0.5 ?Ci/kg of Actimab-A and venetoclax.The enrolled patients had a median of 2 prior therapies (range 2-3) and a median bone marrow blast percentage of 30% (range 20 - >60).  All 3 patients had poor risk disease with adverse cytogenetics, and each patient had an additional high-risk marker (FLT3-ITD+, antecedent JAK2+ myelofibrosis, or TP53 mutation). There were no Actimab-A related dose limiting toxicities or nonhematologic Grade 3 or greater related AEs reported in the first cohort and the trial has advanced to the second dose cohort of 1.0 ?Ci/kg of

For further details see:

Actinium Pharmaceuticals rises 2% after sees 67% ORR in first cohort in Actimab-A/venetoclax combination trial